Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia

Abstract: Before November 2023, CD19 chimeric antigen receptor (CAR) T-cell therapies had not been approved in China for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), leaving a significant unmet need. In response, inaticabtagene autoleucel (Inati-cel), a novel...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ying Wang, Lulu Lv, Yongping Song, Xudong Wei, Hongsheng Zhou, Qifa Liu, Kailin Xu, Dongmei Yan, Cheng Zhang, Shuangyou Liu, Jie Jin, Heng Mei, Ting Niu, Aibin Liang, Runxia Gu, Jienan Ren, Yi Feng, Wei Jin, Yan Zhou, Yiping Deng, Jianxiang Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-02-01
coleção:	Blood Advances
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2473952924006888
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!